| Developers: | Osprey Medical, GE Healthcare |
| Date of the premiere of the system: | August, 2020 |
| Branches: | Pharmaceutics, medicine, health care |
2020: Start of supplies of equipment for decrease in contrast in MRT-inspections from GE Healthcare on the market of the Russian Federation
At the beginning of August, 2020 GE Healthcare announced that it brings the equipment reducing use of contrast in MRT-inspections to the Russian market. Devices for minimization of influence of contrast of DyeVert from the developer of technologies of visualization Osprey Medical will be used with the X-ray contrast GE environments.
The DyeVert system should become a technology platform for inspection of patients with the chronic disease of kidneys (CDK) which will allow to prevent the intense injury of kidneys (IIK) after an intervention coronary angiography.
According to the four-year agreement GE Healthcare will make and advance a portfolio of the Osprey DyeVert devices which are already approved by regulators which allow to reduce use of contrast environments in the market and to trace a cumulative dose of the entered contrast. In each case a system will estimate influence of contrast of rather individual boundary values calculated by indicators of function of kidneys.
The exclusive agreement allows GE Healthcare to commercialize Osprey products in Europe, Russia, in the Middle East, in Africa, Central Asia and Turkey. Considering that Osprey develops new products, GE Healthcare reserves the right in failure to distribution and promotion of new devices in regions.
The president and the chief executive of Osprey Mike McCormick announced in the press release that the company is very glad to cooperation with GE Healthcare.
 | GE Healthcare and Osprey have a common goal - improvement of results of treatment, - the president and the CEO of division of pharmaceutical diagnostics of GE Healthcare Kevin O'Neill added. - We provide specially developed product portfolios and also we hold educational seminars to offer cardiologists an opportunity of safe intervention researches with reduction of risk of OPP.[1] |  |
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |